No Data
No Data
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has maintained a positive development trend; 2) the integration work of the Kunyao Group is progressing steadily; 3) Continued development or introduction of innovative drugs, improved innovative drugs, generic drugs, classic famous recipes, etc. (Mainichi Keizai Shimbun)
China Resources 39 (000999) Review Report: CHC Business Achieves Rapid Growth and Cost Optimization
On April 19, 2024, the company released its 2024 quarterly report. 2024Q1, the company achieved operating income of 7.294 billion yuan (+14.82%) and net profit to mother of 1,364 billion yuan (+18.4)
China Resources 39 (000999): Strong growth under a high base
1Q24 revenue, net non-net profit increased 15% year-on-year, 17%. The company announced 1Q24 revenue of 7.29 billion yuan (+15% yoy), net profit to mother of 1.36 billion yuan (+18% yoy), deducted non-net profit1
Express News | Fangzheng Securities: Branded OTC products+brand+channels have an obvious leading effect
China Resources 39 (000999): Outstanding performance, CHC business drives rapid growth
In the first quarter of 2024, the company's revenue was 7.294 billion yuan, up 14.82% year on year; net profit to mother was 1,364 billion yuan, up 18.49% year on year; net profit after deducting non-return to mother was 1,328 billion yuan, year on year
China Resources 39 (000999): Performance exceeds expectations, core products maintain a good growth trend
1Q24 results were higher than our expectations. The company announced 1Q24 results: revenue of 7.294 billion yuan (YoY +14.82%) and net profit to mother of 1,364 billion yuan (YoY +18.49%), slightly higher than our expectations
No Data